Roche Pharmaceutical Development and Sales Overview
PRAME immunohistochemistry assay
Roche
Enabling optimal patient prognosis via early & accurate diagnosis and treatment of melanoma
Melanoma survival
5 year survival rates
99%
Localized
rates based on
treatment per
stage 1,2
68%
Regional
.
>300k new cases and ~60k death per year caused by Melanoma cancer³
•
30%
Distant
•
Key immunohistochemistry assay to:
Help differentiate between benign and malignant lesions in skin
cancer 4,5
Evaluate tumor margins in known melanoma specimens 4,5
Evaluate sentinel lymph nodes in known melanoma cases 6,7
Localized melanoma is highly curable with a simple surgical excision
Roche's broad dermatology portfolio includes >50 biomarkers
1 American Cancer Society. https://www.cancer.org/cancer/melanoma-skin-cancer/detection-diagnosis-staging/survival-rates-for-melanoma-skin-cancer-by-stage.html; 2 Definitions of stages: 'Localized': There is no sign that the cancer has spread
beyond the skin where it started. 'Regional': The cancer has spread beyond the skin where it started to nearby structures or lymph nodes. 'Distant': The cancer has spread to distant parts of the body, such as the lungs, liver, or skin on other parts of
the body. ³ Cazzato G. et al. Genes. 2022;13: 545; 4 Lezcano, C. et al. Am J Surg Pathol 2018;42(11):1456-1465; 5 Lezcano, C. et al. Surg Pathol Clin 2021 Jun;14(2):165-175; 6 Lezcano, C. et al. Am J Surg Pathol 2020;44(4):503-508; 7 NCCN Guidelines Version
3.2022. PRAME: Preferentially expressed Antigen in Melanoma
40
40View entire presentation